Commentary—Goodbye M(C)ID! Hello MID, Where Do You Come From?

2005/03/10 by Holger J. Schünemann, Gordon Guyatt, Gordon H. Guyatt · 25 citations
Medicine · Economics, Econometrics and Finance · #Chronic Disease Management Strategies #Economic and Financial Impacts of Cancer #Global Cancer Incidence and Screening

paper · doi:10.1111/j.1475-6773.2005.0k375.x

Cited by

• Interpreting the results of patient reported outcome measures in clinical trials: the clinician's perspective. [europepmc]
• How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. [europepmc]
• Measuring patient and clinician perspectives to evaluate change in health-related quality of life among patients with chronic obstructive pulmonary disease. [europepmc]
• The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. [europepmc]
• Minimal Important Difference (MID) of two commonly used outcome measures for foot problems. [europepmc]
• Estimation of minimally important differences in the EQ-5D and SF-6D indices and their utility in stroke. [europepmc]
• Minimally important difference estimates and methods: a protocol. [europepmc]
• Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. [europepmc]
• Checklist to operationalize measurement characteristics of patient-reported outcome measures. [europepmc]
• The Spectrum of Functional Rating Scales in Neurology Clinical Trials. [europepmc]
• Minimal Important Change and Minimal Detectable Change in Activities of Daily Living in Community-Living Older People. [europepmc]
• Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol. [europepmc]
• Network meta-analysis: users' guide for pediatricians. [europepmc]
• Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias. [europepmc]
• Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis. [europepmc]
• Minimal important differences for improvement in shoulder condition patient-reported outcomes: a systematic review to inform a BMJ Rapid Recommendation. [europepmc]
• Opioid versus opioid-free analgesia after surgical discharge: protocol for a systematic review and meta-analysis. [europepmc]
• Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study. [europepmc]
• Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial. [europepmc]
• There is life beyond the statistical significance. [europepmc]
• Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials. [europepmc]
• Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial. [europepmc]
• No difference in patient-reported satisfaction after 12 months between customised individually made and off-the-shelf total knee arthroplasty. [europepmc]
• Minimal important difference and patient acceptable symptom state for the Numerical Rating Scale (NRS) for pain and the Patient-Rated Wrist/Hand Evaluation (PRWHE) for patients with osteoarthritis at the base of thumb. [europepmc]
• A Systematic Review on Cannabinoids for Neuropathic Pain Administered by Routes Other than Oral or Inhalation. [europepmc]